EV Biologics Engages Foley for Intellectual Property Work

26 January 2021 Media Contact: Dan Farrell News

EV Biologics Corp., a Wyoming-based biotechnology company, has engaged Foley to facilitate the propriety development of its exosome technology and technical innovation.


In its announcement, the company cited Foley’s standing at the top of intellectual property law in biotechnology and organics and its specialty in stem cell and extracellular vesicle technology.


Exosomes are nano-sized vesicles that serve as mediators for cell-to-cell communication. The intrinsic properties of exosomes in regulating complex intracellular pathways has advanced their potential utility in the therapeutic control of many diseases, including neurodegenerative conditions and cancer.